KYPROLIS 60 mg Powder For Solution For Injection: Advanced Treatment for Multiple Myeloma

KYPROLIS (carfilzomib) 60 mg Powder For Solution For Injection is a potent proteasome inhibitor designed for the treatment of adults with relapsed or refractory multiple myeloma.

This medication, manufactured by Amgen, plays a crucial role in oncology by targeting and inhibiting proteasomes within cancer cells, leading to their programmed cell death.

Developed with precision, KYPROLIS offers a targeted approach to managing this complex blood cancer.

Its effectiveness is often observed when used in combination with other therapies, providing patients with an enhanced treatment strategy.

For more detailed information and patient support resources, reputable pharmaceutical platforms like NahdiOnline, , and often provide essential product details and availability within their respective regions.

Product Details

• Principle: Carfilzomib
• Strength: 60 mg
• Form: Powder for Solution for Injection
• Manufacturer: Amgen
• Drug Type: Prescription Medicine (POM)
• Package Type: Vial
• Storage: Unopened vials should be stored refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light.

Benefits of Use

• Specifically targets and inhibits proteasomes in myeloma cells, promoting their destruction.
• Effective in treating relapsed or refractory multiple myeloma.
• Can improve progression-free survival in patients, especially when used in combination therapies.
• Offers a critical treatment option for patients who have previously received other therapies.

How to Use

1. KYPROLIS is administered intravenously by a qualified healthcare professional in a clinical setting.
2. The dose is based on the patient's body surface area or a fixed dose, and the administration schedule varies depending on the treatment regimen.
3. The powder in the vial must be reconstituted with Sterile Water for Injection before administration.
4. The reconstituted solution is then diluted in an intravenous bag for infusion.
5. Patients will be closely monitored by their healthcare team throughout the treatment course.

Caution & Warnings

• Cardiac Toxicities: May cause or worsen cardiac failure, myocardial ischemia, and arrhythmias. Patients should be monitored for signs and symptoms.
• Pulmonary Hypertension: Cases of pulmonary hypertension, sometimes severe, have been reported.
• Pulmonary Toxicity: Acute respiratory distress syndrome, acute interstitial lung disease, and pneumonitis may occur.
• Infusion Reactions: Fatal and serious infusion reactions can occur. Prophylactic dexamethasone is recommended.
• Tumor Lysis Syndrome (TLS): Monitor patients for TLS, especially those with a high tumor burden.
• Thrombotic Microangiopathy (TMA): Cases of TMA, including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), have been reported.
• Hepatic Toxicity: Severe and fatal hepatic toxicity has occurred.
• Renal Toxicity: Acute renal failure, sometimes requiring dialysis, has been reported.
• Hypertension: Can cause or worsen hypertension, including hypertensive crisis.
• Posterior Reversible Encephalopathy Syndrome (PRES): Rare cases of PRES have been reported.
• Hemorrhage: Fatal and serious hemorrhage has been reported.
• Embryo-Fetal Toxicity: Can cause fetal harm. Pregnant women should be advised of the potential risk to the fetus.
• Patients should inform their doctor about all medical conditions and medications before starting treatment.

Ingredients

• Active Ingredient: Carfilzomib
• Excipients: Sulfobutylether beta-cyclodextrin sodium (SBECD), Citric acid, Anhydrous.